IMPACT BIOMEDICAL INC.
IBONYSE
$0.46
0.0%Jul 17 close · end-of-day
Price
1Y↓ -33.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$12.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-112.2%
ROIC
-38.4%
Debt / Equity
—
Net Cash
$20,000.00
Return 1Y
-34.6%
Company profile
Impact Biomedical, Inc. (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc., which was incorporated on April 14, 2017. Impact BioMedical Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 1400 Broadfield Blvd., Suite 130, Houston, Texas.
- CEO
- Frank D. Heuszel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Texas
- Website
- www.impactbiomedinc.com
Earnings
IBO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$7,000.00—
Diluted EPS-$0.02↓ -81.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $50,000.00 | — | — | $32,000.00 |
| Gross profit | — | — | — | — |
| Operating income | -$3.4M | -$4.0M | -$28.8M | -$4.3M |
| Net income | -$7.3M | -$4.3M | -$24.7M | -$11.8M |
| Diluted EPS | -$0.10 | -$0.07 | -$2.30 | -$0.38 |
| Operating cash flow | -$2.2M | -$2.9M | -$2.9M | -$1.9M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | -6808.0% | — | — | -13381.3% |
| Net margin | -14510.0% | — | — | -36993.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $7,000.00 | $18,000.00 | — | $7,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$626,000.00 | -$1.1M | -$26.2M | -$1.0M | -$1.2M | -$948,000.00 | -$1.2M | -$2.3M |
| Net income | -$889,000.00 | $4.2M | -$27.1M | -$1.3M | -$14.3M | -$1.5M | $5.2M | -$2.3M |
| Diluted EPS | -$0.09 | $0.06 | -$2.17 | -$0.11 | -$1.18 | -$0.12 | $1.03 | -$0.02 |
| Operating cash flow | -$385,000.00 | -$1.0M | -$986,000.00 | -$682,000.00 | -$694,000.00 | -$613,000.00 | $99,000.00 | -$464,000.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -16471.4% | -5266.7% | — | -32700.0% |
| Net margin | — | — | — | — | -204942.9% | -8166.7% | — | -32671.4% |
Company news
Jun 23, 2025
Mar 21, 2025
Feb 26, 2025
- 509d agoDSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growthfinance.yahoo.com
- 509d agoImpact Biomedical Inc. Announces Acquisition of Celios®, “Protecting People, Plants, and Animals from the World’s Most Dangerous Pathogens With Clean-Room Air Quality”finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-27 | Macko Todd D· Chief Financial Officer | Sale | 43,400 | $0.56 | $24,369.10 | filing |
| 2026-03-25 | Macko Todd D· Chief Financial Officer | Sale | 1,600 | $0.60 | $961.28 | filing |
| 2026-03-23 | Grady Jason | Sale | 50,000 | $0.65 | $32,505.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.